Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study

Abstract

Background: Palmoplantar psoriasis is difficult to treat and often recalcitrant to conventional therapies. Clinical trials have demonstrated the efficacy and safety of secukinumab for this debilitating psoriasis form, but real-life evidence is currently limited. Therefore, here we described the outcomes of patients treated with secukinumab in clinical practice. Research Design and Methods: This was a real-life, retrospective, observational study involving patients with palmoplantar psoriasis treated with secukinumab (300 mg, subcutaneously) at seven dermatologic clinics in Italy. Treatment effectiveness was evaluated based on the changes of the Psoriasis Area and Severity Index (PASI) and palmoplantar (pp) PASI during treatment and by recording safety and tolerability issues over 104 weeks. Results: Forty-three patients initiated treatment with secukinumab. Previous treatments included topical and systemic therapies; half of patients had already tried one or more biologics. Secukinumab improved mean PASI rapidly and substantially with a 78.2% decrease at 16 weeks. Mean ppPASI also improved substantially, but more gradually, with reductions of 55.0% and 79.3% at 16 and 104 weeks, respectively. Approximately half of patients achieved complete skin clearance at 40 weeks. Secukinumab was well tolerated and no relevant treatment-related adverse events were reported. Conclusions: Secukinumab appears to be effective for the treatment of palmoplantar psoriasis also in the real-life setting.

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis

“…In our real-life study, we also showed that secukinumab is effective in the treatment of palmoplantar psoriasis [53]. Forty-three patients were treated with secukinumab.…”

“…Mean ppPASI also substantially improved, but the change was more gradual, with reductions of 55% and 79.3% at 16 and 104 weeks, respectively. Approximately half of the patients achieved complete skin clearance at 40 weeks [53].…”

Real‐life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study

“…The GESTURE study enrolled 205 patients treated with secukinumab with a reduction in mean ppPASI at w16 of 54.5% 6 . These data were also confirmed in a real‐life multicentric Italian experience with 43 patients with a mean ppPASI reduction in 55.0% at 16w and 79.3% at 104w 7 . Data about ppPASI and Ixekizumab are reported in post hoc analysis from UNCOVER1‐2‐3 with higher percentage of patients reaching ppPASI 50 and 75 compared with etanercept (80% vs. 67.8% and 70% vs. 44.1% respectively) 8 …”

“…6 These data were also confirmed in a real-life multicentric Italian experience with 43 patients with a mean ppPASI reduction in 55.0% at 16w and 79.3% at 104w. 7 Data about ppPASI and Ixekizumab are reported in post hoc analysis from UNCOVER1-2-3 with higher percentage of patients reaching ppPASI 50 and 75 compared with etanercept (80% vs. 67.8% and 70% vs. 44.1% respectively). 8 Furthermore, our study showed that patients with higher BMI and multifailure to cDMARDs have a lower probability of response to the drug, a hypothesis that is new and never previously reported.…”

Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study

“…Similar results regarding secukinumab are reported by Galluzzo et al in a real-life multicentre study. Guselkumab was superior to placebo in reaching ppPASI 50 and PGA 0/1 at 16 weeks (60% vs. 21% and 24% vs. 8%, respectively) [16]. In a real-life study including 7 patients treated with tildrakizumab, a ppPASI reduction of 75.5% occurred at week 16 and 100% occurred at week 24 [2].…”